| scholarly article | Q13442814 |
| P2093 | author name string | Shoshana Levy | |
| Ronald Levy | |||
| Adam Widman | |||
| John Timmerman | |||
| Debra K Czerwinski | |||
| Bindu Varghese | |||
| Behnaz Taidi | |||
| James Do | |||
| P2860 | cites work | CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations | Q33193071 |
| Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy | Q35616042 | ||
| Idiotype variant cell populations in patients with B cell lymphoma | Q36353115 | ||
| Therapy of lymphoma directed at idiotypes | Q36577582 | ||
| TLR9 as a key receptor for the recognition of DNA. | Q37080471 | ||
| FcR gamma chain deletion results in pleiotrophic effector cell defects | Q38311129 | ||
| CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response | Q38332055 | ||
| Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas | Q39943861 | ||
| Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. | Q40372837 | ||
| Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics | Q40392451 | ||
| Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. | Q40604062 | ||
| Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. | Q41660798 | ||
| Membrane IgM, IgD, and IgG act as signal transmission molecules in a series of B lymphomas. | Q42819617 | ||
| Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro | Q43949524 | ||
| Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells | Q44263369 | ||
| CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor | Q47722565 | ||
| Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. | Q47725344 | ||
| Clustering of extensive somatic mutations in the variable region of an immunoglobulin heavy chain gene from a human B cell lymphoma | Q48369391 | ||
| Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. | Q54702413 | ||
| [Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody] | Q68093668 | ||
| Regulation of an idiotype+ B cell lymphoma. Effects of antigen and anti-idiotopic antibodies on proliferation and Ig secretion | Q68094611 | ||
| Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants | Q68792567 | ||
| Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon | Q69053865 | ||
| A clinical trial of anti-idiotype therapy for B cell malignancy | Q69891840 | ||
| Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody | Q72657705 | ||
| Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma | Q73235550 | ||
| Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells | Q73386737 | ||
| CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens | Q73492223 | ||
| Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies | Q74213454 | ||
| CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma | Q77167886 | ||
| Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy | Q80159179 | ||
| Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself | Q80736139 | ||
| CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice | Q80934188 | ||
| B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides | Q81474815 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4477-4485 | |
| P577 | publication date | 2009-09-17 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees | |
| P478 | volume | 114 |
| Q43249169 | Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms. |
| Q36891034 | Depleting tumor-specific Tregs at a single site eradicates disseminated tumors |
| Q47940254 | Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges. |
| Q34194680 | In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study |
| Q90257528 | Intratumoral Immunotherapy-Update 2019 |
| Q47281370 | Intratumoral immunotherapy: using the tumor as the remedy |
| Q38358045 | Paradigm shift in oncology: targeting the immune system rather than cancer cells |
| Q38174058 | Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients. |
| Q36850457 | TLR agonists: our best frenemy in cancer immunotherapy |
| Q37863518 | Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies |
Search more.